The stock price of Genprex Inc (NASDAQ: GNPX) has plunged by -0.76 when compared to previous closing price of 0.23, but the company has seen a -15.54% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-22 that Research Journal Features Genprex Collaborators’ Abstract Detailing Positive Preclinical Data on the Use ofReqorsa® Gene Therapy for the Treatment of Lung Cancer AUSTIN, Texas, April 22, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators’ abstract was published in the online Proceedings supplement of Cancer Research, a scientific journal published by the American Association for Cancer Research (AACR). Genprex collaborators will present the published abstract in a poster presentation at the 2025 AACR Annual Meeting being held April 25-30, 2025 in Chicago, Illinois.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The 36-month beta value for GNPX is also noteworthy at -0.28. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GNPX is 23.49M, and at present, short sellers hold a 1.18% of that float. The average trading volume of GNPX on April 22, 2025 was 4.06M shares.
GNPX’s Market Performance
The stock of Genprex Inc (GNPX) has seen a -15.54% decrease in the past week, with a -37.53% drop in the past month, and a -67.87% fall in the past quarter. The volatility ratio for the week is 11.60%, and the volatility levels for the past 30 days are at 19.44% for GNPX. The simple moving average for the past 20 days is -22.37% for GNPX’s stock, with a -74.72% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -35.39% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.54% of loss for the given period.
Volatility was left at 19.44%, however, over the last 30 days, the volatility rate increased by 11.60%, as shares sank -40.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.26% lower at present.
During the last 5 trading sessions, GNPX fell by -16.48%, which changed the moving average for the period of 200-days by -88.43% in comparison to the 20-day moving average, which settled at $0.2874. In addition, Genprex Inc saw -73.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
The total capital return value is set at -13.07. Equity return is now at value -467.24, with -285.38 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.83.
Conclusion
In summary, Genprex Inc (GNPX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
